OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar
Ahmed Zaqout, Muna Almaslamani, Hiam Chemaitelly, et al.
International Journal of Infectious Diseases (2022) Vol. 124, pp. 96-103
Open Access | Times Cited: 21
Ahmed Zaqout, Muna Almaslamani, Hiam Chemaitelly, et al.
International Journal of Infectious Diseases (2022) Vol. 124, pp. 96-103
Open Access | Times Cited: 21
Showing 21 citing articles:
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA
Mindy M. Cheng, Carolina Reyes, Sacha Satram, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 2, pp. 607-621
Open Access | Times Cited: 44
Mindy M. Cheng, Carolina Reyes, Sacha Satram, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 2, pp. 607-621
Open Access | Times Cited: 44
Real-World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients
Neil R. Aggarwal, Laurel Beaty, Tellen D. Bennett, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 12, pp. 2129-2136
Open Access | Times Cited: 50
Neil R. Aggarwal, Laurel Beaty, Tellen D. Bennett, et al.
The Journal of Infectious Diseases (2022) Vol. 226, Iss. 12, pp. 2129-2136
Open Access | Times Cited: 50
All-cause and COVID-19 mortality in Qatar during the COVID-19 pandemic
Asma Ali Al-Nuaimi, Hiam Chemaitelly, Sandy Semaan, et al.
BMJ Global Health (2023) Vol. 8, Iss. 5, pp. e012291-e012291
Open Access | Times Cited: 26
Asma Ali Al-Nuaimi, Hiam Chemaitelly, Sandy Semaan, et al.
BMJ Global Health (2023) Vol. 8, Iss. 5, pp. e012291-e012291
Open Access | Times Cited: 26
Change in effectiveness of sotrovimab for preventing hospitalization and mortality for at-risk COVID-19 outpatients during an Omicron BA.1 and BA.1.1-predominant phase
Neil R. Aggarwal, Laurel Beaty, Tellen D. Bennett, et al.
International Journal of Infectious Diseases (2022) Vol. 128, pp. 310-317
Open Access | Times Cited: 26
Neil R. Aggarwal, Laurel Beaty, Tellen D. Bennett, et al.
International Journal of Infectious Diseases (2022) Vol. 128, pp. 310-317
Open Access | Times Cited: 26
Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature review
Myriam Drysdale, Mehmet Berktaş, Daniel C. Gibbons, et al.
Infection (2024) Vol. 52, Iss. 5, pp. 1839-1861
Open Access | Times Cited: 5
Myriam Drysdale, Mehmet Berktaş, Daniel C. Gibbons, et al.
Infection (2024) Vol. 52, Iss. 5, pp. 1839-1861
Open Access | Times Cited: 5
Evaluating Hospital Admission Data as Indicators of COVID-19 Severity: A National Assessment in Qatar
Layan Sukik, Hiam Chemaitelly, Houssein H. Ayoub, et al.
Open Forum Infectious Diseases (2025) Vol. 12, Iss. 3
Open Access
Layan Sukik, Hiam Chemaitelly, Houssein H. Ayoub, et al.
Open Forum Infectious Diseases (2025) Vol. 12, Iss. 3
Open Access
SARS-CoV-2 neutralizing antibody bebtelovimab – a systematic scoping review and meta-analysis
Mabel Nyit Yi Liew, Kok Pim Kua, Shaun Wen Huey Lee, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
Mabel Nyit Yi Liew, Kok Pim Kua, Shaun Wen Huey Lee, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 10
Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review
Myriam Drysdale, Daniel C. Gibbons, Moushmi Singh, et al.
Infection (2023) Vol. 52, Iss. 1, pp. 1-17
Open Access | Times Cited: 10
Myriam Drysdale, Daniel C. Gibbons, Moushmi Singh, et al.
Infection (2023) Vol. 52, Iss. 1, pp. 1-17
Open Access | Times Cited: 10
Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 subvariant predominance: a systematic literature review
Myriam Drysdale, Daniel C. Gibbons, Moushmi Singh, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 9
Myriam Drysdale, Daniel C. Gibbons, Moushmi Singh, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 9
Effectiveness of Sotrovimab and Molnupiravir in community settings in England across the Omicron BA.1 and BA.2 sublineages: emulated target trials using the OpenSAFELY platform
John Tazare, Linda Nab, Bang Zheng, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 8
John Tazare, Linda Nab, Bang Zheng, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 8
Turning point in COVID-19 severity and fatality during the pandemic: a national cohort study in Qatar
Hiam Chemaitelly, Houssein H. Ayoub, Jeremy Samuel Faust, et al.
BMJ Public Health (2023) Vol. 1, Iss. 1, pp. e000479-e000479
Open Access | Times Cited: 8
Hiam Chemaitelly, Houssein H. Ayoub, Jeremy Samuel Faust, et al.
BMJ Public Health (2023) Vol. 1, Iss. 1, pp. e000479-e000479
Open Access | Times Cited: 8
Experience with sotrovimab treatment of SARS‐CoV‐2‐infected patients in Denmark
Line Dahlerup Rasmussen, Anne‐Mette Lebech, Anne Øvrehus, et al.
British Journal of Clinical Pharmacology (2022) Vol. 89, Iss. 6, pp. 1820-1833
Open Access | Times Cited: 11
Line Dahlerup Rasmussen, Anne‐Mette Lebech, Anne Øvrehus, et al.
British Journal of Clinical Pharmacology (2022) Vol. 89, Iss. 6, pp. 1820-1833
Open Access | Times Cited: 11
A turning point in COVID-19 severity and fatality during the pandemic: A national cohort study in Qatar
Hiam Chemaitelly, Houssein H. Ayoub, Jeremy Samuel Faust, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 5
Hiam Chemaitelly, Houssein H. Ayoub, Jeremy Samuel Faust, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 5
Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections
Naoyuki Miyashita, Yasushi Nakamori, Makoto Ogata, et al.
Viruses (2023) Vol. 15, Iss. 6, pp. 1300-1300
Open Access | Times Cited: 4
Naoyuki Miyashita, Yasushi Nakamori, Makoto Ogata, et al.
Viruses (2023) Vol. 15, Iss. 6, pp. 1300-1300
Open Access | Times Cited: 4
SARS‐CoV‐2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: A national cohort study
Mai Mahmoud, Houssein H. Ayoub, Peter Coyle, et al.
Influenza and Other Respiratory Viruses (2023) Vol. 17, Iss. 11
Open Access | Times Cited: 4
Mai Mahmoud, Houssein H. Ayoub, Peter Coyle, et al.
Influenza and Other Respiratory Viruses (2023) Vol. 17, Iss. 11
Open Access | Times Cited: 4
Use of Sotrovimab in Pregnancy: Experiences from the COVID-19 International Drug Pregnancy Registry
Diego F. Wyszynski, Lydia Demetriou, Cheryl Renz, et al.
Drug Safety (2024) Vol. 47, Iss. 9, pp. 843-851
Open Access | Times Cited: 1
Diego F. Wyszynski, Lydia Demetriou, Cheryl Renz, et al.
Drug Safety (2024) Vol. 47, Iss. 9, pp. 843-851
Open Access | Times Cited: 1
An Overview of the Strategies to Boost SARS-CoV-2-Specific Immunity in People with Inborn Errors of Immunity
Emma Chang-Rabley, Menno C. van Zelm, Emily Ricotta, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 675-675
Open Access | Times Cited: 1
Emma Chang-Rabley, Menno C. van Zelm, Emily Ricotta, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 675-675
Open Access | Times Cited: 1
Pooled analysis of the MANTICO2 and MONET randomized controlled trials comparing drug efficacy for early treatment of COVID-19 during Omicron waves
Valentina Mazzotta, Fulvia Mazzaferri, Simone Lanini, et al.
Journal of Infection (2024) Vol. 89, Iss. 5, pp. 106294-106294
Open Access | Times Cited: 1
Valentina Mazzotta, Fulvia Mazzaferri, Simone Lanini, et al.
Journal of Infection (2024) Vol. 89, Iss. 5, pp. 106294-106294
Open Access | Times Cited: 1
Real world effectiveness of sotrovimab in preventing COVID-19–related hospitalisation or death in patients infected with Omicron BA.2
Alwaleed Abdulaziz Behzad, Aamal Mohamed, Ahmed Ali, et al.
Journal of Infection and Public Health (2023) Vol. 17, Iss. 2, pp. 315-320
Open Access | Times Cited: 3
Alwaleed Abdulaziz Behzad, Aamal Mohamed, Ahmed Ali, et al.
Journal of Infection and Public Health (2023) Vol. 17, Iss. 2, pp. 315-320
Open Access | Times Cited: 3
Safety of Sotrovimab use in children with COVID-19: an Italian experience
Elisabetta Venturini, Lara Fusani, Andrea Lo Vecchio, et al.
Journal of Chemotherapy (2023) Vol. 36, Iss. 1, pp. 45-48
Closed Access | Times Cited: 1
Elisabetta Venturini, Lara Fusani, Andrea Lo Vecchio, et al.
Journal of Chemotherapy (2023) Vol. 36, Iss. 1, pp. 45-48
Closed Access | Times Cited: 1
Real-world effectiveness of sotrovimab for the treatment of SARS-CoV-2 infection during Omicron BA.2 and BA.5 subvariant predominance: a systematic literature review
Myriam Drysdale, Mehmet Berktaş, Daniel C. Gibbons, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
Myriam Drysdale, Mehmet Berktaş, Daniel C. Gibbons, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 1
